Linvoseltamab pivotal data presented at aacr reinforce high response rate that deepens over time in patients with heavily pre-treated multiple myeloma

Regulatory applications for linvoseltamab currently under review by the u.s. food and drug administration (fda) and european medicines agency (ema) regulatory applications for linvoseltamab currently under review by the u.s. food and drug administration (fda) and european medicines agency (ema)

REGN Ratings Summary

REGN Quant Ranking